JP2019521105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521105A5 JP2019521105A5 JP2018563888A JP2018563888A JP2019521105A5 JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5 JP 2018563888 A JP2018563888 A JP 2018563888A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2019521105 A5 JP2019521105 A5 JP 2019521105A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- antibody
- polymorphism
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346683P | 2016-06-07 | 2016-06-07 | |
| US62/346,683 | 2016-06-07 | ||
| PCT/IB2017/053245 WO2017212375A1 (en) | 2016-06-07 | 2017-06-01 | Anti-c5 antibody for treating patients with complement c5 polymorphism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521105A JP2019521105A (ja) | 2019-07-25 |
| JP2019521105A5 true JP2019521105A5 (https=) | 2020-07-09 |
Family
ID=59078125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563888A Pending JP2019521105A (ja) | 2016-06-07 | 2017-06-01 | 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190225678A1 (https=) |
| EP (1) | EP3464351A1 (https=) |
| JP (1) | JP2019521105A (https=) |
| CN (1) | CN109328197A (https=) |
| WO (1) | WO2017212375A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| JP7813222B2 (ja) | 2019-08-16 | 2026-02-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度抗ｃ５製剤 |
| JP7798763B2 (ja) * | 2019-10-25 | 2026-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ５関連疾患の治療または予防のための投与レジメン |
| EP4423271A2 (en) | 2021-10-28 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| CN119409815B (zh) * | 2025-01-07 | 2025-04-08 | 天辰生物医药(苏州)有限公司 | 抗人补体c5 vhh抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| JP2010521194A (ja) * | 2007-03-22 | 2010-06-24 | ノバルティス アーゲー | Ｃ５抗原およびその使用 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| LT2894165T (lt) * | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| EP2824111B1 (en) * | 2010-04-30 | 2017-03-22 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
| TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| EP2975055A4 (en) * | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN107428823B (zh) * | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
-
2017
- 2017-06-01 EP EP17731296.4A patent/EP3464351A1/en not_active Withdrawn
- 2017-06-01 JP JP2018563888A patent/JP2019521105A/ja active Pending
- 2017-06-01 WO PCT/IB2017/053245 patent/WO2017212375A1/en not_active Ceased
- 2017-06-01 US US16/306,654 patent/US20190225678A1/en not_active Abandoned
- 2017-06-01 CN CN201780034701.9A patent/CN109328197A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521105A5 (https=) | ||
| Dimachkie et al. | Chronic inflammatory demyelinating polyneuropathy | |
| Wieszczycka et al. | Lanthanides and tissue engineering strategies for bone regeneration | |
| Leyhe et al. | Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study | |
| JP2017518316A5 (https=) | ||
| Tent et al. | Midfacial fractures: A retrospective etiological study over a 10-year period in Western Romanian population | |
| Battaglia et al. | Guillain-Barré syndrome following severe head trauma and spine surgery | |
| Fatima et al. | Amyloid-β clearance with monoclonal antibodies: transforming Alzheimer’s treatment | |
| HK1248534A1 (zh) | 周围神经的igg刺激髓鞘再生 | |
| Du et al. | The ageing immune system as a potential target of senolytics | |
| Kim et al. | Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma | |
| Sarbaz et al. | Medical and Surgical Complications in Three Tertiary Hospitals in the Northeast of Iran: A Multicenter Study. | |
| Ong et al. | Thrombotic paradox: ischaemic stroke in immune thrombocytopaenia. A case report and review | |
| EP3632447A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES | |
| KR20230145401A (ko) | 항-N3pGlu 아밀로이드 베타 항체 및 그의 용도 | |
| Stevelink et al. | Epilepsy surgery in patients with genetic refractory epilepsy: A systematic review | |
| Berg et al. | Peripheral neuropathies: corticosteroids and antivirals in Bell palsy | |
| Nobile-Orazio et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders | |
| Natalia et al. | COSTS FOR REVERSE HEMOSTATIC THERAPY OF INTERNAL CEREBRAL BLEEDING WITH THE USE OF PROTHROMBIN COMPLEX CONCENTRATE | |
| Olupot-Olupot et al. | Effects of hydroxyurea treatment on malaria infections in Sub-Saharan Africa | |
| Ahmad et al. | AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions. | |
| Monje et al. | DI-022 Real life effectiveness and safety of lenalidomide in the treatment of multiple myeloma | |
| WO2017034906A8 (en) | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies | |
| BEZDITKO | PHARMACOECONOMIC ANALYSIS OF PROTROMBIN COMPLEX CONCENTRATE (OCTAPLEX PREPARATION) USE IN INTRACEREBRAL HEMORRHAGE | |
| Khaybullin et al. | Chronic inflammatory demyelinating polyneuropathy and related syndromes: diagnosis and treatment |